1. A method for preventing primary breast or breast cancer in a subject, comprising administering a therapeutically effective amount of a RANKL inhibitor to a specified patient. A method of treating primary breast or breast cancer in a subject, comprising administering a therapeutically effective amount of a RANKL inhibitor to a specified patient to reduce (number) of cancer cells or prevent cancer from progressing in the tissue being the tissue from which said primary breast or breast cancer is derived. 3. An RANKL inhibitor for use in the treatment or prevention of primary breast cancer or breast cancer, wherein said inhibitor inhibits the binding of RANKL to RANK, and the treatment is used to reduce (number) of cancer cells or to prevent cancer from progressing in the tissue being the tissue from which Indicated primary breast cancer or breast cancer occurs. 4. An RANKL inhibitor for use in the treatment or prevention of primary breast or breast cancer in a patient, wherein the patient is treated with female sex hormones, preferably hormone replacement therapy, preferably progesterone or progestin, or a hormonal contraceptive, while the inhibitor inhibits the binding of RANKL to RANK .5. RANKL inhibitor for use in the treatment or prevention of primary breast or breast cancer in a patient in combination with the treatment of female sex hormones, in particular hormone replacement therapy, or for use in combination with a hormonal contraceptive, in particular1. Способ предотвращения первичного рака груди или рака молочной железы у субъекта, включающий введение терапевтически эффективного количества ингибитора RANKL указанному пациенту.2. Способ лечения первичного рака груди или рака молочной железы у субъекта, включающий введение терапевтически эффективного количества ингибитора RANKL указанному пациенту для уменьшения (количества) раковых клеток или предотвращения прогрессирования рака в ткани, являющейся тканью, из которой происходит указанный первичный рак груди
